This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
F-18 fluoroestradiol (FES) PET may improve staging of grade 1 or 2 estrogen receptor (ER)-positive breast cancer compared with F-18 FDG-PET, according to an article published March 4 in Radiology. The tumor in the right breast (T4N0M0, grade 3 ductal carcinoma) is visible on both PETscans.
This persistent inflammation increases atrophy of gray matter in the brain, yet is difficult to assess on MRIscans, the authors explained. The researchers performed F-18 PBR06 PETscans on 22 patients with MS and eight healthy controls. The full article is available here.
“To date, F-18 FDG PET findings are currently not taken into account when making a diagnosis for possible, probable, or definite neurosarcoidosis,” noted lead author Jessy Chen, MD, of Charité - Berlin University Medicine, and colleagues. The article was published January 25 in Neurological Research and Practice.
The group previously described developing the AI model in an article published last year. In this case, a 43-year-old man underwent an MRIscan that showed no contrast enhancement, yet hyperintensities were apparent in the patient’s left thalamus and frontoparietal region. Image courtesy of the Journal of Nuclear Medicine.
All patients underwent F-18 PI-2620 PET imaging, as well as amyloid PET, MRI, and neuropsychologic tests at baseline and at follow-up after one year. in 15 patients with negative amyloid PETscans; 1.18 in A link to the full article can be found here. in 20 late-onset patients, and 1.54
He also has co-authored more than 350 peer-reviewed articles, with his work appearing in top-tier publications including the Journal of Clinical Oncology, JAMA Oncology, and the International Journal of Radiation Oncology, Biology, Physics.
In this article, we’ll delve into the hottest news and breakthroughs in imaging, highlighting the remarkable strides that have made the headlines. Further prospective longitudinal MRI studies are essential to elucidate causality in this context.
PETscans have revealed for the first time what may be a key molecular driver of stress and addiction in people with alcohol use disorder (AUD), according to a study published January 21 in Neurobiology of Stress. According to the findings, PETscans revealed 41.7% The full article is available here.
This standard has revolutionized the radiology industry, encompassing many imaging modalities such as X-rays, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, nuclear medicine, PETscans, etc.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content